KKR to acquire Immedica Pharma, a Stockholm-based pharmaceutical company focused on rare diseases
Acquiring Company
Kohlberg Kravis Roberts
Acquired Company
Immedica Pharma AB
New York
SwedenEnergyFinancial ServicesReal EstateFinanceReal Estate InvestmentVenture CapitalAngel InvestmentRenewables & EnvironmentBiotechnologyHealth CarePharmaceuticalDescription
KKR, a leading global investment firm, has agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. KKR, along with existing owner Impilo, will work together to support Immedica’s continued growth, including the launch of the recently approved ultra-orphan drug Loargys, additional pipeline assets, and an expansion into the U.S. market.
Quick answer
Kohlberg Kravis Roberts is acquiring Immedica Pharma AB, announced April 23, 2024. Kohlberg Kravis Roberts is based in New York, New York, United States.
- How much did Kohlberg Kravis Roberts pay for Immedica Pharma AB?
- The deal value was not disclosed.
- What does Kohlberg Kravis Roberts do?
- Kohlberg Kravis Roberts (KKR) is a leading global investment firm that manages multiple asset classes, including private equity, energy, infrastructure, real estate, and credit.
- Where are Kohlberg Kravis Roberts and Immedica Pharma AB based?
- Kohlberg Kravis Roberts is based in New York, New York, United States. Immedica Pharma AB is based in Sweden.
- Who are the decision-makers at Kohlberg Kravis Roberts?
- Fundz holds 5 contacts at Kohlberg Kravis Roberts. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Energy and Financial Services
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- KKR acquires SunFireMatrix, Inc. to drive transformation in healthcare landscape (April 2, 2024)
- KKR to Acquire Majority Ownership in Agiloft to Fuel Expansion and Innovation (May 30, 2024)
- KKR completes acquisition of mdf commerce to bolster digital commerce capabilities (May 20, 2024)
- KKR acquires two-building Class A logistics property in Nashville Airport submarket (May 13, 2024)
- Ares Real Estate completes acquisition of Hotel Portfolio from Landsec to strengthen real estate holdings (May 9, 2024)
- Pinegrove Capital Partners' Affiliate to Acquire SVB Capital's Investment Platform Business (May 4, 2024)
Who to call at Kohlberg Kravis Roberts, and when
When Kohlberg Kravis Roberts changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Kohlberg Kravis Roberts raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kohlberg Kravis Roberts, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kohlberg Kravis Roberts. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kohlberg Kravis Roberts makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Immedica Pharma AB?
Immedica Pharma AB was acquired by Kohlberg Kravis Roberts, based in New York. The deal was reported on April 23, 2024. Kohlberg Kravis Roberts (KKR) is a leading global investment firm that manages multiple asset classes, including private equity, energy, infrastructure, real estate, and credit. Kohlberg Kravis Roberts is publicly traded (KKR) and operates in Energy.
When did Kohlberg Kravis Roberts acquire Immedica Pharma AB?
Kohlberg Kravis Roberts's acquisition of Immedica Pharma AB was reported on April 23, 2024. KKR, a leading global investment firm, has agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Immedica Pharma AB do?
Immedica is a pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products. The company covers marketing and sales, compliance, and medical affairs, serving patients in over 50 countries. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.